Perforated ulcer

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
Friday, March 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Statement from the Prevent Cancer Foundation on updated guidance for colorectal cancer screening from the American College of Physicians

Retrieved on: 
Monday, July 31, 2023
Bleeding, Prevent Cancer Foundation, National Colon Cancer Awareness Month, Fear, Cancer, Large intestine, Risk, Perforated ulcer, Organization, Incidence, Colorectal cancer, National Cancer Institute, Patient, American College of Gastroenterology, Colonoscopy, Confusion, Mortality, American Cancer Society, Transport, American College, NCI, American College of Physicians, ACP, USPSTF, Dietary supplement, Medical imaging, Dairy

Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.

Key Points: 
  • Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.
  • The Prevent Cancer Foundation strongly opposes the updated guidance, which goes against the latest evidence-based screening recommendations from the organizations working in the cancer screening space every day.
  • The Prevent Cancer Foundation supports following the guidelines of the USPSTF, the American Cancer Society and American College of Gastroenterology and encourages all adults of average risk to begin colorectal cancer screening at age 45.
  • There are several options available for colorectal cancer screening, and all available colorectal cancer screening methods are safe and can save lives.

Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

Retrieved on: 
Tuesday, January 17, 2023
European Patent Office, Perforated ulcer, CDI, Person, Immuron, European Patent Bulletin, IMC, Clostridioides difficile (bacteria), Risk, European Patent Convention, ASX, Patient, Sepsis, CDC, USD, Toxic megacolon, Pharmaceutical industry, Clostridioides, European

Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No.

Key Points: 
  • Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No.
  • The company previously reported it had received notification from the European Patent Office of the intent to grant in July last year (ASX announcement July 7, 2022).
  • The European registration adds to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the United States.
  • Clostridioides difficile (previously known as Clostridium difficile) infection (CDI) is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile.

TerSera® to sponsor "NET Cancer Health Storylines" digital platform to support patients suffering from Carcinoid Syndrome Diarrhea

Retrieved on: 
Wednesday, December 7, 2022
Therapy, Carcinoid syndrome, Mnet, Flatulence, Angioedema, Headache, Impact of the COVID-19 pandemic, CYP3A4, Patient, History, Contraindication, Anxiety, Hormone, Carcinoid, Rash, Union, Wilms' tumor, Partnership, Perforated ulcer, Medication, Fatigue, Defecation, Abdominal pain, Clinical trial, Constipation, Serotonin, Itch, Google Play, Learning, Diarrhea, SSA, Liver, Bradykinin, CYP2B6, Health, Quality of life, Absorption, NETS, Water, Medtech, Obstruction, CCF, Peripheral edema, Drug, Nausea, FDA, App Store (iOS/iPadOS), CSD, Depression, NET, Appetite, Pharmaceutical industry, Generic drug, Telotristat ethyl, Fever, Biotechnology, Pharma, CS

"We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.

Key Points: 
  • "We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.
  • The resources available through this platform are important tools in supporting NET patients throughout their journey," said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation.
  • "Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program.
  • The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968.

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
Quality of life, Polyphagia, Prader–Willi syndrome, Choking, GLOBE, Intellectual disability, Perforated ulcer, Body composition, Growth hormone, Cardiovascular disease, Puberty, Diabetes, PWS, Orphan, Research, Mortality, Therapy, SEC, Obesity, NASDAQ, Medicine, Behavioral Problems, Achievement, Securities Exchange Act of 1934, Caregiver, Company, Diazoxide, Degenerative disease, Patient, Analysis, CMC, Acquisition, NDA, Income, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022.
  • The fair value was estimated to be approximately$9.4 million as of September 30, 2022, a $0.1 million increase from the estimate as of June 30, 2022.
  • Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in Dublin

Retrieved on: 
Wednesday, October 5, 2022
CDC, Constipation, Epithelium, White Blood Cells, Infection, Clostridioides difficile (bacteria), Feces, QIDP, Virulence, Toxic megacolon, Diarrhea, CDI, Patient, Clostridioides difficile infection, Perforated ulcer, Collection, GI, Subclinical infection, Centers for Disease Control and Prevention, ISIN, Center, Vomiting, Company, Physiology, Gram-positive bacteria, Blood, Disease, Incidence, Bacteria, Recurrence, Vancomycin, Ileus, Intubation, Heart, Global health, FDA, Pharmaceutical industry, Vaccine, Dietary supplement, Antibiotics, Clostridioides

Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.

Key Points: 
  • Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.
  • The diarrhea episodes improved after 6 days of treatment and came back to normal 10 days after treatment after a transient constipation period.
  • Georges Gaudriault, Chief Scientific Officer of DEINOVE who attended the ESCMID/ASM conference in Dublin specifies: The use of DNV3837 is a potential paradigm shift.
  • Located at the heart of the Euromedecine park in Montpellier, DEINOVE has been listed on EURONEXT GROWTH (ALDEI - code ISIN FR0010879056) since 2010.

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Retrieved on: 
Monday, October 3, 2022
Degenerative disease, Body composition, GLOBE, Securities Exchange Act of 1934, NASDAQ, Mortality, SEC, Prader–Willi syndrome, Behavioral Problems, Polyphagia, Obesity, Choking, Food, Diazoxide, Puberty, Medicine, Caregiver, Perforated ulcer, Therapy, Orphan, Quality of life, Cardiovascular disease, Patient, PWS, Growth hormone, Diabetes, Company, Intellectual disability, Pharmaceutical industry

Initiation of the randomized withdrawal period of Study C602 represents a significant milestone for our late-stage DCCR development program, saidAnish Bhatnagar, M.D., Chief Executive Officer of Soleno.

Key Points: 
  • Initiation of the randomized withdrawal period of Study C602 represents a significant milestone for our late-stage DCCR development program, saidAnish Bhatnagar, M.D., Chief Executive Officer of Soleno.
  • The randomized withdrawal period of Study C602 is a multi-center, randomized, double-blind, placebo-controlled study of DCCR in approximately 80 patients with PWS at 17 sites in the U.S. and 5 sites in the U.K.
  • This randomized withdrawal period consists only of patients currently enrolled in Study C602 and will not enroll any new patients.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Olympus Announces U.S. Distribution of EndoClot Polysaccharide Hemostatic Spray and EndoClot Submucosal Injection Agent

Retrieved on: 
Monday, September 12, 2022
Laparoscopy, Hemostasis, Olympus, CO2, Perforated ulcer, Safety, Adenoma, Bleeding, Polyp, Endoscopy, Assistant, Blood, Perforation, Accuracy and precision, GI, PHS, Patient, Pressure regulator, Physician, Dissection, Technology, Quality of life, Air compressor, Cedars-Sinai Medical Center, Atmosphere of Earth, Ulcerative colitis, AMP, SIS, Gastrointestinal bleeding, EPI, ESD, Water, Multimedia, Classification, Artifact, Variable-speed air compressor, Starch, Pharmaceutical industry, Medical imaging, Birth control, Medical device, Conveyor system, MD, Medicine

CENTER VALLEY, Pa., Sept. 12, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today it will distribute EndoClot® Polysaccharide Hemostatic Spray and EndoClot® Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc. (EPI), which joined with Olympus in a U.S. distribution agreement earlier in the year.

Key Points: 
  • Based on EndoClot AMP Technology, Submucosal Injection Solution (SIS) and Polysaccharide Hemostatic Spray (PHS) Systems Assist with Submucosal Lift and Hemostasis During GI Procedures
    CENTER VALLEY, Pa., Sept. 12, 2022 /PRNewswire/ --Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today it will distribute EndoClot Polysaccharide Hemostatic Spray and EndoClot Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc. (EPI), which joined with Olympus in a U.S. distribution agreement earlier in the year.
  • The starch-derived AMP technology has demonstrated an excellent safety profile.iThe EndoClot AMP particles work by absorbing water from blood.
  • "We see great advantage in being able to identify the bleed and address it at the same time."
  • The EndoClot PHS System enables physicians to apply an advanced powder hemostat during a procedure using controlled, consistent air pressure through a portable air compressor.

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
ENDO, FDA, PWS, Polyphagia, Cardiovascular disease, NDA, Intellectual disability, Growth hormone, Obesity, Mortality, GLOBE, Securities Exchange Act of 1934, SEC, Achievement, Behavioral Problems, Research, Perforated ulcer, Caregiver, Congress, European, Income, Prader–Willi syndrome, Patient, Quality of life, Therapy, Degenerative disease, Company, European Society of Endocrinology, International, Acquisition, Safety, NASDAQ, Orphan, Diazoxide, Tablet, Diabetes, Choking, Food and Drug Administration, Conference, CMC, Food, Medicine, Puberty, Body composition, Pharmaceutical industry, Tutoring, EU, Endocrinology

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2022.
  • Long-term clinical data showing improvement in metabolic parameters and body composition following treatment with DCCR tablets in patients with PWS presented at ENDO 2022.
  • Data on the ongoing safety and efficacy of DCCR in PWS patients at presented the 2022 European Congress of Endocrinology.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.